Corcept Therapeutics Incorporated has submitted a Marketing Authorization Application $(MAA)$ to the European Medicines Agency $(EMA)$ for relacorilant as a treatment for patients with platinum-resistant ovarian cancer. The submission is based on positive data from Phase 2 and pivotal Phase 3 ROSELLA trials, which showed improved progression-free and overall survival with relacorilant plus nab-paclitaxel compared to nab-paclitaxel alone, with a similar safety profile. Additionally, the U.S. Food and Drug Administration (FDA) is currently reviewing Corcept's application to market relacorilant for the same indication, with a Prescription Drug User Fee Act (PDUFA) target action date set for July 11, 2026. No grant or funding from multiple organizations was mentioned.